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UbiquitinationTo analyze the proteins interacting with the severe acute respiratory syndrome coronavirus (SARS-CoV)
envelope (E) protein, a SARS-CoV was engineered including two tags associated to the E protein. Using this
virus, complexes of SARS-CoV E and other proteins were puriﬁed using a tandem afﬁnity puriﬁcation system.
Several viral and cell proteins including spike, membrane, non-structural protein 3 (nsp3), dynein heavy
chain, fatty acid synthase and transmembrane protein 43 bound E protein. In the present work, we focused
on the binding of E protein to nsp3 in infected cells and cell-free systems. This interaction was mediated by
the N-terminal acidic domain of nsp3. Moreover, nsp3 and E protein colocalized during the infection. It was
shown that E protein was ubiquitinated in vitro and in cell culture, suggesting that the interaction between
nsp3 and E protein may play a role in the E protein ubiquitination status and therefore on its turnover..
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Severe acute respiratory syndrome coronavirus (SARS-CoV) was
identiﬁed as the etiological agent of a respiratory disease that emerged in
Guangdong Province, China, in late 2002, and rapidly spread to 32
countries (Drosten et al., 2003; Fouchier et al., 2003; Ksiazek et al., 2003;
Kuikenet al., 2003;Marra et al., 2003; Peiris et al., 2003;Rota et al., 2003).
After July 2003, only a fewcommunity-acquired and laboratory-acquired
SARS cases were reported (http://www.who.int/csr/sars/en/). The
disease causes an atypical pneumonia with an average mortality of 10%.
No clearly deﬁned efﬁcacious treatment is available to prevent or treat
SARS.
SARS-CoV is an enveloped, single-stranded positive-sense RNA virus
with a genome of 29.7 kb that belongs to genus β of the Coronavirinae
subfamily (de Groot et al., 2008; Enjuanes et al., 2008; Gorbalenya, 2008).
The replicase gene is encoded within the 5′ two-thirds of the SARS-CoV
genome, including two overlapping open reading frames (ORF) named
ORFs 1a and 1b, the latter being translated by a ribosomal frameshift
upstreamof the ORF 1a stop codon (Brierley et al., 1989; Thiel et al., 2003;
Ziebuhr, 2005). Translation of bothORFs in the cytoplasmof infected cells,
results in the synthesis of two polyproteins, pp1a and pp1ab, that are
processed by two viral proteinases to yield 16 functional non-structural
proteins (nsps) (Ziebuhr, 2005; Ziebuhr et al., 2000). Thesenon-structural
proteins are the components of the membrane-anchored replication–transcription complex (Stertz et al., 2007). The largest non-structural
protein of SARS-CoV is the multifunctional nsp3 protein that comprises
1922 amino acid residues. It has been proposed that nsp3 could act as a
replication/transcription scaffolding protein (Imbert et al., 2008). At least
seven domains have been identiﬁed in nsp3 based on amino acid
secondary structure prediction, phylogenetic conservation, structure and
functional analysis (Snijder et al., 2003; Thiel et al., 2003). These domains
are: (i) the N-terminal acidic domain, called nsp3a, that adopts a
ubiquitin-like globular fold (Serrano et al., 2007); (ii) the ADP-ribose-
1″-phosphatase (ADRP), named nsp3b (Saikatendu et al., 2005); (iii) the
SARS unique domain (SUD), also called nsp3c, that binds RNA G
quadruplexes (Tan et al., 2009); (iv) the nsp3d domain that contains
two subdomains involved in the papain-like proteinase (PL2pro) activity
(Harcourt et al., 2004), and another onewith a ubiquitin-like fold; and (v)
the additional domains (nsp3e–g) that include a RNA binding domain, a
transmembrane (TM) region and a zinc ﬁnger motif. In a recent report
nsp3 has been shown to be an interferon antagonist (Devaraj et al., 2007).
In this sense, the papain-like protease domain has a deubiquitinating
activity that shows a deISGylation activity that could be involved in the
inhibition of interferon responses (Barretto et al., 2005; Devaraj et al.,
2007; Frieman et al., 2009; Lindner et al., 2005, 2007). Posttranslational
modiﬁcation of proteins by ubiquitin and ubiquitin-like ligands is a
multistep process, carried out by a well-deﬁned enzymatic pathway,
which is required tomaintain physiological levels and functional activities
of several cellular proteins. In addition, the reversal pathway, named
deubiquitination, has been recognized as an important process in the
regulation of protein degradation by the proteasome. Many viruses have
evolved mechanisms to modify host ubiquitination and deubiquitination
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immune responses and to enhance virus replication and egress (Isaacson
and Ploegh, 2009). In this sense, it has been shown that several viral
proteins are directly modiﬁed by ubiquitin or ubiquitin-like proteins
during the virus cycle. Moreover, some viruses encode their own
ubiquitinating or deubiquitinating enzymes thatmay alter the ubiquitina-
tion level of cellular and viral targets (Isaacson and Ploegh, 2009).
The CoV replicase complex is involved in genome replication and
transcription of a nested set of subgenomic mRNAs (sgmRNAs)
encoding structural proteins, such as the spike (S), envelope (E),
membrane (M), and nucleocapsid (N). In addition, SARS-CoV sgmRNAs
encode a set of group speciﬁc proteins, whose sequence and number
differ from other coronavirus species (Enjuanes et al., 2008). In the case
of SARS-CoV, someof theseproteins (3a, 6, 7a, and7b)alsoare structural
proteins (Huang et al., 2006, 2007; Ito et al., 2005; Schaecher et al., 2007;
Shen et al., 2005). The function of most group speciﬁc proteins is still
unclear. However, these proteins may inﬂuence the virus–host
interaction and viral pathogenesis.
SARS-CoV E protein is a small integral membrane protein that is 76
amino acids in length and contains a short hydrophilic amino terminus
followed by a hydrophobic region and a hydrophilic carboxy terminus
(Torres et al., 2007; Wilson et al., 2004). It has been shown that SARS-
CoV E protein plays an important, but not well-deﬁned role in virus
assembly and budding. The SARS-CoV E gene has previously been
shown to be a non-essential gene, although deletion of this gene from
the viral genome reduces virus titers in cultured cells by 20- to 200-fold
in relation to the wild-type virus (SARS-CoV-wt), depending on the cell
type infected (DeDiego et al., 2007). SARS-CoV lacking the E gene is
attenuated in the highly sensitive hACE-2 transgenic mouse model and
in hamsters, and it has been proposed that the E gene is a virulence
factor (DeDiego et al., 2007, 2008).
The identiﬁcation of proteins interacting with SARS-CoV E protein is
relevant to understand the mechanisms of action of this protein during
the viral cycle. In this article, we report the construction of a
recombinant SARS-CoV expressing E protein linked to two tandem
afﬁnity tags [inﬂuenza haemmaglutinning (HA) and a FLAG epitope]
spaced by a tobacco etch virus (TEV) cleavage site throughout the C
terminus of E protein. This system allowed the rapid puriﬁcation of E
and associated proteins from SARS-CoV-infected cells. Using this
system, the interaction of SARS-CoV envelope protein with structural
proteins S and M, and with the multifunctional protein nsp3 was
identiﬁed. In addition, the binding of E protein to cellular proteins
including dynein heavy chain, fatty acid synthase, aminopeptidase
puromycin sensitive, transmembrane protein 43 and lactate dehydro-
genase A is shown. In this paper, we focused on E-nsp3 binding thatwas
mediated through theN-terminal ubiquitin-likedomain-1of nsp3 in the
absenceofother viral proteins.Moreover, these twoproteins colocalized
in the cytoplasm of SARS-CoV infected cells. In this report, evidence
showing that E protein is ubiquitinated in cells is also provided. Taken
together these data showed an interaction of SARS-CoV structural E
protein with a replicase component (nsp3), that could be implicated in
the virus life cycle inﬂuencing E protein ubiquitination and turnover.
Results
Generation of a recombinant SARS-CoV expressing a tagged E protein
To identify the proteins that interact with SARS-CoV E protein, a
recombinant SARS-CoV expressing the E protein fused to a tag on its
carboxy terminus was engineered as a BAC (pBAC-SARS-CoV-EtagCt)
(Fig. 1A). The tag contains the FLAG epitope followed by a TEV
protease site, and the HA epitope. Vero E6 cells were transfected with
this plasmid or with a parental plasmid encoding the wt SARS-CoV
(pBAC-SARS-CoVFL) that lacks E protein associated tags. Recombinant
viruses rSARS-CoV-EtagCt and rSARS-CoV-wt were recovered from
both plasmids with high titers and showed the characteristiccytopathic effect induced by SARS-CoV infection (data not shown).
The recombinant virus expressing tagged E protein was ampliﬁed,
cloned by three rounds of plaque isolation, and passaged twice to
generate a virus stock.
To study the stability of the rSARS-CoV-EtagCt virus, the synthesis
of sgmRNAs by the recombinant viruses after being passaged 8 times,
was characterized by RT-PCR (Fig. 1B). Total RNA frommock-infected
cells or cells infected with the SARS-CoV-wt, the virus lacking the E
gene (rSARS-CoV-ΔE), or the SARS-CoV-EtagCt virus were isolated
and ampliﬁed by RT-PCR. E, M and N gene sgmRNAs were ampliﬁed
using a forward primer complementary to the leader sequence and
reverse primers speciﬁc for each gene. A band corresponding towild-
type E mRNA was detected in cells infected with the parental SARS-
CoV while no band was detected in SARS-CoV-ΔE-infected cells, as
expected. In the case of cells infected with SARS-CoV-EtagCt, a PCR
product of 340 bp corresponding to mRNA encoding the tagged E
protein was identiﬁed (Fig. 1B). The sequence of this PCR product
maintained the sequence introduced in the SARS-CoV-EtagCt virus.
No differences in the PCR products derived from the mRNA encoding
M and N proteins were detected (Fig. 1B). To study tagged E protein
expression, extracts from mock-infected cells, or cells infected with
SARS-CoV-wt, SARS-CoV-ΔE or SARS-CoV-EtagCt were analyzed by
Western blot (Fig. 1C). A SARS-CoV E protein-speciﬁc monoclonal
antibody generated in our laboratory was used to detect the
expression of this protein (J. L. Nieto-Torres, M. L. DeDiego, E.
Alvarez, and L. Enjuanes, CNB-CSIC, Madrid, Spain). A band
corresponding to E protein was detected in SARS-CoV-wt-infected
cells while no bandwas observed in cells infectedwith SARS-CoV-ΔE.
As expected, a band of lower electrophoretic mobility, corresponding
to tagged E protein, was detected in cells infected with SARS-CoV-
EtagCt. The densitrometric scanning of those bands showed only ∼5%
difference between E-wt and E-tag, indicating that the expression of
tagged E protein is unaffected by the extra sequence added to E. In
addition, using FLAG or HA epitope speciﬁc monoclonal antibodies, a
band corresponding to tagged E protein was observed in cells
infected with SARS-CoV-EtagCt, whereas no bands were detected in
both SARS-CoV-wt or SARS-CoV-ΔE-infected cells (Fig. 1C), indicat-
ing that the E-tagged protein maintained both epitopes. As a control
of infection, SARS-CoV N protein was detected in all the viruses
(Fig. 1C). No differences in N protein expression levels were detected
between cells infected with SARS-CoV-wt, SARS-CoV-ΔE and SARS-
CoV-EtagCt.
To analyze whether the expression of viral mRNAs downstream
of E gene is unaffected by the tag sequence added to this gene,
synthesis of genomic and sgmRNAs was quantiﬁed by Q-RT-PCR
(Fig. 2). The quantiﬁcations showed that the amount of viral
mRNAs in cells infected with SARS-CoV-EtagCt were within a
twofold range relative to the corresponding control cells
infected with SARS-CoV-wt or SARS-CoV-ΔE, indicating that the E
protein tag does not affect signiﬁcantly the expression of viral
mRNAs.
Growth kinetics of SARS-CoV-EtagCt virus was analyzed both in
Vero E6 and Huh-7 cells in comparison with the parental virus and
SARS-CoV-ΔE (Fig. 3). SARS-CoV-EtagCt and wt viruses showed
similar growth kinetics and virus titers in both cell lines. In contrast,
the titer of the rSARS-CoV-ΔE virus was ∼20- and ∼200-fold lower
than those of the recombinant wild-type and SARS-CoV-EtagCt
viruses in Vero E6 and Huh-7 cells, respectively. This result suggested
that the E protein fused to a tag is as functional as the wild-type one
since a virus containing a tagged E protein grew to the same extent as
the wild-type virus.
Puriﬁcation and identiﬁcation of SARS-CoV E protein ligands
Vero E6 cells were infected with SARS-CoV-EtagCt virus, and the E-
tag protein complexes were puriﬁed by two afﬁnity chromatography
Fig. 1. Generation of a recombinant SARS-CoV expressing a tagged E protein. (A) Scheme of recombinant virus expressing tagged E protein. L, leader sequence; REP, replicase gene; S,
spike protein, E, envelope protein; M, membrane protein; N, nucleocapsid protein; pA, poly(A) tail; FLAG, FLAG epitope; TEV, tobacco etch virus protease site; and HA, inﬂuenza
haemmaglutinin epitope. (B) Vero E6 cells were mock infected (Mock) or infected with the recombinant wild-type (WT), the rSARS-CoV-ΔE (ΔE) or rSARS-CoV-EtagCt (E-tag)
viruses. Viral mRNA expression was analyzed by RT-PCR using the oligonucleotides speciﬁc for sgmRNAs of E, M and N genes. (C)Western blot analysis of infected cell lysates using E,
FLAG, HA and N protein-speciﬁc antibodies followed by peroxidase-labelled goat anti-rabbit or anti-mouse antibodies.
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the same puriﬁcation was performed with mock- or SARS-CoV-wt-
infected cell extracts. Cell lysates were applied to an anti-HA resin and
bound proteins were eluted by proteolytic cleavage of the tag at the
TEV protease site. Eluates from the proteolytic cleavage on the anti-
HA resin were incubated with an anti-FLAG agarose and proteins
bound to matrix were eluted by speciﬁc competition with FLAG
peptide. To identify proteins that copuriﬁed with E-tag, the elutedFig. 2. Virus RNA synthesis in infected Vero E6 cells. Vero E6 cells were infected with
rSARS-CoV-wt (black boxes), rSARS-CoV-ΔE (grey boxes) or rSARS-CoV-EtagCt (white
boxes) at an moi of 0.5. Total RNA was extracted at 16 h post-infection and the
accumulation of viral genomic or subgenomic messenger RNA (sgmRNA) of genes M, 6
and N was quantiﬁed by Q-RT-PCR. Levels of viral RNAs are represented in comparison
to reference levels from cells infected with SARS-CoV-wt. The experiment was
performed three times and the data represent the average of triplicates. Standard
deviation is indicated as error bars.proteins were separated by SDS-PAGE and visualized by Coomassie
blue staining. In the case of puriﬁcations from cells infected with
SARS-CoV-EtagCt, several protein bands were detected, whereas
puriﬁcations in parallel using extracts from mock-infected cells or
cells infected with the wild-type virus did not reveal any detectable
protein band (Fig. 4A). These data indicated that the proteins
identiﬁed speciﬁcally bound to E-tag protein. Some of the bands
were excised, digested with trypsin, and subjected to MALDI TOF/TOF
mass spectrometry to identify the corresponding proteins by
screening against the available NCBI protein database. A set of 12
proteins was reproducibly identiﬁed in at least two out of four
experiments with signiﬁcant MASCOT scores (pN0.05) (Table 1).
Among the identiﬁed proteins binding to E, the viral proteins nsp3, S
and M were identiﬁed as E protein interacting partners. In addition,
the proteins dynein heavy chain, fatty acid synthase, aminopeptidase
puromycin sensitive, phosphofructokinase platelet, tubulin alpha and
beta, actin beta, transmembrane protein 43 and lactate dehydroge-
nase A, were identiﬁed as cellular proteins interacting with E protein.
This paper is focused on the interaction of E protein with nsp3.
Interaction between E and nps3 proteins
The interaction between nsp3 and E protein detected with the
tandem afﬁnity puriﬁcation was conﬁrmed by coimmunoprecipita-
tion. To this end, protein complexes formed in Vero E6 cells infected
with SARS-CoV-wt, SARS-CoV-ΔE, or mock-infected cells were
pulled down using antibodies speciﬁc for E and nsp3 proteins.
Immune precipitates were analyzed by Western blot using the anti-
E and anti-nsp3 antibodies (Fig. 4B). Using an E protein-speciﬁc
antibody, nsp3 was coimmunoprecipitated in samples derived from
wild-type infected cells but not in extract derived from mock or
Fig. 3. Growth kinetics of the recombinant viruses in monkey and human cells. Vero E6 (A), and Huh-7.5.1 (B) cells were infected at an moi of 0.5 with the recombinant wild-type
virus (WT), the rSARS-CoV-ΔE (ΔE) or the rSARS-CoV-EtagCt (E-tag). At different times post-infection, virus titers were determined by plaque assay on Vero E6 cells. Error bars
represent standard deviations of the mean of results from three experiments.
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down nsp3, E protein coimmunoprecipitated in extracts from cells
infected with SARS-CoV-wt, but not in those from mock-infected cells,
or cells infected with SARS-CoV-ΔE. In contrast, no speciﬁc bands were
observed in control experimentswhere the immunoprecipitationswere
performed with a monoclonal antibody speciﬁc for the N protein ofFig. 4. Identiﬁcation of viral proteins interacting with SARS-CoV E protein. (A) Puriﬁcation of
extracts from mock-infected cells or cells infected with rSARS-CoV-wt (wt) or rSARS-CoV-
detected by staining gels with Coomassie blue dye. Bands were excised from gels andwere id
Extracts from Vero E6 cells infected with rSARS-CoV-wt or rSARS-CoV-ΔE were immunoprec
analyzed by Western blot using E and nsp3 protein-speciﬁc antibodies followed by peroxidtransmissible gastroenteritis virus (TGEV). The amount of E or nsp3
proteins coimmunoprecipitated by antibodies speciﬁc for nsp3 or E
proteins respectively was relatively low, suggesting that in the
experimental conditions used, the binding between these two proteins
was relativelyweak. Overall, these results indicated that E protein forms
complexes with nsp3 protein.proteins interacting with E protein using a tandem afﬁnity puriﬁcation method. Vero E6
EtagCt (E-tag) were used in a double afﬁnity chromatography. Puriﬁed proteins were
entiﬁed bymass spectrometry. (B) Coimmunoprecipitation assays of nsp3 and E protein.
ipitated with nsp3, E or TGEV N protein-speciﬁc antibodies. Immunoprecipitations were
ase-labelled goat anti-rabbit or anti-mouse antibodies.
Table 1
Proteins isolated with SARS-CoV E-tagged protein.
Accession no. Protein name Mr Functiona Masses matched/searched Score/threshold/databaseb Nc
gi|34555776 Dynein, heavy chain isoform 1 488,642 Microtubule-based transport 8/16 73/65/nr 3
gi|41584442 Fatty acid synthase 275,900 Lipid metabolism 14/33 99/80/nr 2
gi|34555776 SARS-CoV non-structural protein (nsp3) 216,607 Virus protein 30/49 315/80/nr 3
gi|30027620 SARS-CoV spike glycoprotein (S protein) 141,323 Virus protein 15/26 247/80/nr 3
gi|15451907 Aminopeptidase puromycin sensitive 99,125 Cell cycle 24/75 187/80/nr 3
gi|119606901 Phosphofructokinase platelet 93,725 Glycolysis 17/55 83/65/Hs 2
gi|14389309 Alpha tubulin 50,548 Cytosqueleton 27/94 566/80/nr 4
gi|18088719 Beta tubulin 50,096 Cytosqueleton 35/85 558/70/m 3
gi|4501885 Beta actin 42,052 Cytosqueleton 26/78 516/80/nr 4
gi|13236587 Transmembrane protein 43 44,904 Nuclear membrane 24/77 453/80/nr 3
gi|62897717 Lactate dehydrogenase A 36,951 Metabolism 13/93 131/80/nr 3
gi|30027623 SARS-CoV membrane protein (M protein) 25,070 Virus protein 1/83 42/36/Vs 3
gi|29836499 SARS-CoV E protein 8360 Virus protein 1/80 58/37/Vs 1
a Biological process according to Gene Ontology.
b Mascot scores are given in boldface. Mascot threshold scores indicate the limit score fromwhich the identiﬁcationwas signiﬁcant (pb0.05). Searches were performed against the
NCBI database without restrictions (nr). In the indicated cases taxonomy was restricted to humans (Hs), mammals (m) or viruses (Vs).
c Number of times that the protein was identiﬁed.
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coimmunoprecipitation assay was performed using nsp3-derived
fragments expressed in a cell-free coupled transcription–translation
system (Fig. 5A). Biotinylated Lys-tRNA was used in translation
reactions for subsequent detection of the expressed proteins with
streptavidin conjugated to peroxidase (Fig. 5B). Recombinant
puriﬁed SARS-CoV E protein was added to translation lysates and
then E protein was pulled down using the speciﬁc monoclonal
antibody indicated above. Fragment 1 of nsp3 was coimmunopreci-
pitated together with E protein, while no bands were detected in a
control experiment in which the porcine reproductive and respira-
tory syndrome virus (PRRSV) glycoprotein 5 (Gp5) was added to
translation lysates and pulled downwith anti-Gp5 antibody (Fig. 5B).Fig. 5. Coimmunoprecipitation assays of nsp3 fragments. (A) Scheme of nsp3-derived frag
domains are shown in the scheme: UB1, ubiquitin-like domain 1; AC, acidic hypervariable d
like domain 2; PLP, papain-like protease; NAB, group II-speciﬁc domain; G2M, group II-speciﬁ
Synthesized fragments were mixed with recombinant E or Gp5 proteins and then we
Immunoprecipitations were analyzed by Western blot using E and Gp5 protein-speciﬁc a
Luciferase (Luc) was used as a control.Overall, these results indicated that the interaction between nsp3
and E protein is independent of the presence of other SARS-CoV
proteins, and that the interaction site in nsp3 is located in the N-
terminal domain of the protein.
Mapping the nsp3 region required to interact with E protein in cell-free
systems
To further delimit the domain of nsp3 involved in the interaction
with E protein, the N-terminal acidic domain (UB1-AC), the ADRP, and
the SUD domains of nsp3 protein were expressed in cell-free systems
as described above (Fig. 6A). Puriﬁed E or Gp5 proteins were mixed
with each of the nsp3 N-terminal biotinylated polypeptides andments synthesized in TNT® coupled reticulocyte lysate systems (F1 to F4). The nsp3
omain; ADRP, ADP-ribose-1″-phosphatase; SUD, SARS unique domain; UB2, ubiquitin-
c maker; TM, transmembrane motif; ZF, putative metal-binding region; and Y, Y region.
re used in immunoprecipitation assays using E or Gp5 protein-speciﬁc antibodies.
ntibodies followed by peroxidase-labelled goat anti-rabbit or anti-mouse antibodies.
Fig. 6. Mapping the nsp3 region required to interact with E protein. (A) Scheme of nsp3-F1-derived fragments synthesized in TNT® coupled reticulocyte lysate systems (UB1-AC,
ADRP and SUD). The nsp3 domains are shown in the scheme: UB1, ubiquitin-like domain 1; AC, acidic hypervariable domain; ADRP, ADP-ribose-1″-phosphatase; SUD, SARS unique
domain; UB2, ubiquitin-like domain 2; PLP, papain-like protease; NAB, group II-speciﬁc domain; G2M, group II-speciﬁc marker; TM, transmembrane motif; ZF, putative metal-
binding region; and Y, Y region. Synthesized fragments were mixed with recombinant E or Gp5 proteins and then were used in immunoprecipitation assays using E or Gp5 protein-
speciﬁc antibodies. Immunoprecipitations were analyzed by Western blot using E and Gp5 protein-speciﬁc antibodies followed by peroxidase-labelled goat anti-rabbit or anti-
mouse antibodies.
Fig. 7. Colocalization of nsp3 and E proteins. Vero E6 cells grown on glass coverslips were infected with rSARS-CoV-wt, rSARS-CoV-ΔE or rSARS-CoV-EtagCt at an moi of 0.5. At 15 h
post-infection the cells were ﬁxed with 8% paraformaldehyde. Cells were labelled with nsp3 (red) or HA (green) speciﬁc antibodies.
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Fig. 8.Ubiquitination of SARS-CoV E protein. Ubiquitin conjugation to E protein. Vero E6
cells were transiently transfected with the plasmid mixtures shown in the ﬁgure. The
control plasmid pcDNA was used to equalize the total amount of transfected plasmid in
all cases. 24 h after transfection, the cells were lysed by Laemmli lysis buffer followed by
boiling for 5 min. The denatured lysates were analyzed by SDS-PAGE and Western blot
with an antibody against E protein (A) or HA epitope (B). (C) In vitro ubiquitination of
SARS-CoV E protein. Baculovirus puriﬁed E protein was incubated with mono-ubiquitin
(mUb) or poly-ubiquitin (pUb) in the presence of the all the enzymes of the
ubiquitination process. The reactions were resolved by SDS-PAGE and transferred to
nitrocellulose. The ubiquitinated (Ub-E) and non-ubiquitinated E protein was detected
by Western blot using a speciﬁc antibody against E protein.
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unrelated protein Gp5, as a negative control (Fig. 6B). While no
bands were detected in a control experiment when Gp5 was used as
bait, a band corresponding to UB1-AC domain was observed in
samples in which puriﬁed E protein was added to the translation
mixtures and subsequently immunoprecipitated with E speciﬁc
antibody (Fig. 6B). Moreover, bands corresponding to ADRP and
SUD domains were not coimmunoprecipitated together with E
protein (Fig. 6B). This data indicates that nps3 interacts with E
protein through the ubiquitin-like domain-1 located in the N-
terminus of the protein.
Subcellular localization of E and nsp3
To obtain complementary support for the interaction between nsp3
and E protein, Vero E6 cells infected with SARS-CoV-wt, SARS-CoV-ΔE
and SARS-CoV-EtagCt were analyzed by confocal immunomicroscopy
using HA (to detect E-tag) or nsp3 speciﬁc antibodies. All infected cells
showing the presence of E protein also stained with the nsp3 speciﬁc
antibody giving an identical pattern, consistent with a perinuclear
distribution (Fig. 7). The localization of the tagged E protein was the
same as untagged E in infected cells indicating that the tag sequence did
not change the E protein localization (Supplementary Fig. 1). These
results suggest that nsp3 and E protein colocalize in the cytoplasm of
infected cells and that the absence of E protein did not change the
subcellular distribution of nsp3.
Ubiquitination of SARS-CoV E protein
To analyze whether E protein is ubiquitinated, a plasmid
expressing E protein was cotransfected with a plasmid expressing a
modiﬁed ubiquitin (Ub-OK) fused to a His tag into VeroE6 cells. The
modiﬁed ubiquitin prevents the formation of poly-ubiquitin chains
and the subsequently degradation of poly-ubiquitinated proteins by
the proteasome. The cells were lysed 24 h post transfection, the
proteins were resolved by SDS-PAGE and E protein was detected by
Western blotting using an antibody E protein speciﬁc (Fig. 8A). An
additional band corresponding to monoubiquitinated E protein was
detected only when E protein was expressed in presence of Ub-OK
(Fig. 8A, lane 3). By contrast, samples from cells expressing E protein
(Fig. 8A, lane 2) or Ub-OK (Fig. 8A, lane 1) alone did not show the
novel band. The promyelocytic leukemia protein (PML) was
expressed in parallel to serve as a positive control of ubiquitination
(Fig. 8B). In this case, different lower migrating bands corresponding
to different ubiquitination states of the protein were observed. This
result indicates that SARS-CoV E protein was ubiquitinated in
transfected cells.
To further analyze E protein ubiquitination, an in vitro assay was
performed using recombinant puriﬁed E protein expressed using
baculoviruses, followed by immunoblotting detection of E protein
with anE speciﬁc antibody. A slowmigrating E bandwas detectedwhen
E protein was incubated with presence of mono-ubiquitin or poly-
ubiquitin (Fig. 8C, lanes 2 and 3), whereas no additional band was
detected when E protein was incubated in the absence of ubiquitin
(Fig. 8, lane 1), indicating that SARS-CoV E protein is also ubiquitinated
in a cell-free system.
Discussion
Coronavirus E protein is present in a high copy number in the
cytoplasm of infected cells but is a minor component of the virions
(Godet et al., 1992; Liu and Inglis, 1991; Yu et al., 1994). It plays
important roles in coronavirus assembly andmorphogenesis (Fischer et
al., 1998; Ortego et al., 2007, 2002), alteration of the cellular membrane
permeability (Liao et al., 2004, 2006) and virus–host interaction (Liu et
al., 2007). In this study, we used a TAP approach coupled to massspectrometry to identify viral proteins interacting with SARS-CoV E
protein that could be important to regulate its functions. This led to the
observation of interactions between the E and other viral structural
proteins such as S and M. Cellular proteins signiﬁcantly binding to E
protein were also identiﬁed, as dynein heavy chain, fatty acid synthase,
aminopeptidase puromycin sensitive, phosphofructokinase platelet,
tubulin alpha and beta, actin beta, transmembrane protein 43 and
lactate dehydrogenase A. The interaction between E andM coronavirus
proteins has already been reported in other CoV species, such as
infectious bronchitis virus (IBV) and mouse hepatitis virus (MHV), by
coimmunoprecipitation in virus-infected or transfected cells (Corse and
Machamer, 2003; Lim and Liu, 2001; Maeda et al., 1999). The role of
SARS-CoV E protein in virus assembly has been analyzed studying the
formation of VLPs both in mammalian and insect cells (Ho et al., 2004;
Huang et al., 2004; Mortola and Roy, 2004; Siu et al., 2008), and by
reverse genetics (DeDiego et al., 2007, 2008). Although there are
conﬂicting reports on the proteins necessary for the formationof VLPs in
SARS-CoV (Hoet al., 2004;Huang et al., 2004;Mortola and Roy, 2004), it
has been clearly shown that a recombinant virus lacking E gene
produced virions with the samemorphology as the wt virus, indicating
that E protein is not necessary to obtain infectious SARS-CoV (DeDiego
et al., 2007, 2008).
In addition to the interaction of E protein with S and M, a novel
interaction between E protein and the non-structural protein nsp3
was identiﬁed. The nsp3-E interaction was detected by reciprocal
coimmunoprecipitation of lysates from SARS-CoV-infected cells.
Furthermore, nsp3 and E protein colocalized in the perinuclear
region of the cytoplasm of SARS-CoV-infected cells. Taken together,
these data suggest that nsp3 and E protein may form a protein
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CoV proteins has been studied using different approaches (yeast
two-hybrid assay, mammalian two-hybrid assay and coimmuno-
precipitation) (Pan et al., 2008; von Brunn et al., 2007). Studies using
a two-hybrid system have shown the interaction of E protein with
nsp1, nsp8, nsp11, 3b, 7b and 9b proteins (von Brunn et al., 2007).
Some of these interactions were conﬁrmed by coimmunoprecipita-
tion of proteins expressed in human HEK 293-transfected cells. In
addition, interaction between E and 7a proteins was detected using a
mammalian two-hybrid assay, although this interaction was not
conﬁrmed by coimmunoprecipitation nor pull-down approaches
(Pan et al., 2008). Nevertheless, these articles did not describe the
interaction between E protein and the structural proteins M and S, or
the non-structural nsp3 protein. This was probably due to the
limitation of two-hybrid systems in detecting proteins with
transmembrane domains that could prevent the transfer of bait–
ligand complexes to the cell nucleus, where these complexes lead to
transcription. The system described here, allowed the identiﬁcation
of E protein interacting partners in the context of SARS-CoV
infection overcoming potential limitations of two-hybrid assays.
Interestingly, a recent report identifying the SARS-CoV structural
proteins showed that, in addition to the well know structural
proteins S, E, M, and N, nsp3 is a tentative novel minor virion
component (Neuman et al., 2008). A network of protein–protein
interactions within SARS-CoV components has been proposed
(Neuman et al., 2008). In this network, the interaction between
nsp3 and E protein could, in principle, be explained by an indirect
link through the 9b protein in the virion. Nevertheless, we have
demonstrated in an in vitro coimmunoprecipitation assay that nsp3
speciﬁcally interacts with E protein in the absence of other viral
proteins. This data suggested that the interaction of nsp3 with E
protein is most likely a direct interaction, although the requirement
of proteins from the reticulocyte lysate assay could not be formally
excluded.
Nsp3 is a multifunctional protein of the replication/transcription
complex. It has recently been proposed that nsp3 may act as a
replication/transcription scaffolding protein (Imbert et al., 2008). In
this report, it has been shown that nsp3, in particular the PLP domain,
interacted with a large number of partners of the replication/
transcription complex. This data in combination with the presence
of a transmembrane domain within nsp3 suggested that this protein
could act bringing several proteins into close proximity, within the
double membrane environment. In the present report, we showed
that E colocalized with nsp3 in the cytoplasm during the infection. In
this sense, nsp3 may bring the E protein into the vicinity of the
replication/transcription complex.
It has been shown that ubiquitination and deubiquitination
processes are important in the viral life cycle (Isaacson and Ploegh,
2009). Several viral proteins possess deubiquitinating activity. One
of them is the PLpro domain of the SARS-CoV nsp3 protein that
belongs to the USP family of deubiquitinases (DUBs) and has
deubiquinatin activity in vitro (Lindner et al., 2005). Moreover, it
has been proposed that the PLpro domain might act protecting the
viral replication complex from proteasomal degradation via deubi-
quitination. However, the viral and cellular targets of the nsp3 DUB
domain remain completely unknown. Here, we describe that SARS-
CoV E protein is ubiquitinated in vitro and in cells, although the
function of this post-translational modiﬁcation in the course of
infection is not known. Nps3-E interaction could have a role in
controlling the ubiquitination status of E protein during the
infection and, as a consequence, on its turnover and modulation
of the innate and adaptative immune responses or virus replication
and egress, similarly to what has been suggested in other viral
systems (Isaacson and Ploegh, 2009).
In conclusion, our work describes a system to detect interactions
between the E protein with other viral and cellular components in theinfection context. We describe a novel protein–protein interaction
between the structural protein E and the non-structural protein nsp3
and that this interaction was mediated through the N-terminal
ubiquitin-like domain-1 of nsp3 in the absence of other viral proteins.
This work also describes that SARS-CoV E protein is ubiquitinated
both in vitro and in cells. Further investigation will be needed to
clarify the role of E protein ubiquitination in viral cycle and virus–host
interaction, and whether nsp3 plays a role in E protein ubiquitination.Materials and methods
Cells and culture conditions
African green monkey kidney-derived Vero E6 cells and the Huh-
7.5.1 clone derived from the human hepatome Huh-7 cells were
kindly provided by E. Snijder (University of Leiden, The Netherlands)
and F. V. Chisari (Scripps Research Institute, La Jolla, California, USA),
respectively. In both cases, cells were cultured in Dulbecco's modiﬁed
Eagle medium (DMEM, GIBCO, Grand Island, NY, USA) supplemented
with 25 mM HEPES and 10% fetal bovine serum (FBS, Biowhittaker,
Berviers, Belgium). Virus growth and titrations were performed in
Vero E6 cells following standard procedures previously described in
detail (DeDiego et al., 2007). All work with infectious virus was
performed in biosafety level (BSL) 3 facilities by personal wearing
positive-pressure air purifying respirators (3 M HEPA AirMate, Saint
Paul, MN).Construction of plasmid pBAC-SARS-CoV-EtagCt
The pBAC-SARS-CoV-EtagCt plasmid encoding a rSARS-CoV expres-
sing theE gene fused to a tag consisting on the FLAGand theHAepitopes
separated by TEV cleavage site, was constructed from a previously
generated full-length infectious cDNA clone (plasmid pBAC-SARS-
CoVFL) (Almazan et al., 2006). The tagged E gene was introduced by
overlap extension PCR using the plasmid pBAC-SARS-CoVFL. The
oligonucleotides SARS-E-VS (5′-CTCTTCAGGAGTTGCTAATCCAG-
CAATGG-3′) and SARS-EtagCt-RS (5′-GAGCTCACCCTGAAAATA-
CAAATTCTCCTTATCGTCGTCATCCTTGTAATCGACCAGAAGATCAG-
GAACTCC-3′), which includes the TEV site and the FLAG epitope
followed by a sequence complementary from the nucleotides (nt)
26325 to 26348 of the SARS-CoV genome, were used to generate a PCR
product from nt 26018 to 26348 of the SARS-CoV genome. The
oligonucleotides SARS-EtagCt-VS (5′-GAGAATTTGTATTTTCAGGGT-
GAGCTCTACCCATACGATGTTCCAGATTACGCTTAAGATCTTCTGGTC-
TAAACGAACTAACTATTATTATTATTC-3′), which contains the TEV site
and the HA epitope followed by a sequence from nt 26334 to 26372 of
the SARS-CoV genome, and SARS-29794-RS (5′-CCAGGTCGGACCGC-
GAGGAGGTG-3′) were used to generate a PCR product spanning nt
26334 to 29794 of the pBAC-SARS-CoVFL plasmid. Both overlapping
products were used as templates for PCR ampliﬁcation using primers
SARS-E-VS and SARS-29794-RS. The ﬁnal PCR product was digested
with the enzymes BamHI and RsrII and cloned into pBAC-SARS-CoVFL
digested with the same enzymes to generate the plasmid pBAC-SARS-
CoV-EtagCt.Transfection and recovery of infectious viruses from cDNA clones
Baby hamster kidney (BHK) cells were grown to 90% conﬂuence in
12.5 cm2 ﬂasks and were transfected with 6 µg of pBAC-SARS-CoV-
Etag-Ct or pBAC-SARS-CoVFL, as a control, using 18 µg of
Lipofectamine 2000 (Invitrogen) according to the manufacturer's
instructions. Recovered viruses were cloned by plaque titration as
described in detail (Almazan et al., 2006; DeDiego et al., 2007).
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Vero E6 or Huh-7.5.1 cells grown to 90% conﬂuence were
infected at a multiplicity of infection (moi) of 0.05 with the viruses
rSARS-CoV-wt, rSARS-CoV-ΔE or rSARS-CoV-EtagCt. Culture super-
natants were collected at different times post-infection, and virus
titers were determined as previously described (DeDiego et al.,
2007).
Western blot analysis
Proteins were resolved by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE), transferred to a nitrocellulose
membrane by wet immunotransfer and processed for Western
blotting. The blots were probed with monoclonal antibodies speciﬁc
for FLAG tag (dilution 1:1000; Sigma), HA tag (dilution 1:10,000;
Sigma) or PRRSV Gp5 protein (dilution 1:1000; INGENASA, Madrid,
Spain) or polyclonal antibodies against E (dilution 1:6000; kindly
provided by Shen Shuo, Institute of Molecular and Cellular Biology,
Singapore), nsp3 (dilution 1:2000; Rockland, Gilbertsville, PA), or N
proteins (dilution 1:2000; Imgenex). Horseradish peroxidase-conju-
gated antibodies against the different species and the Immobilon
Western chemiluminescent substrate (Millipore) were used to detect
bound antibodies. Chemiluminescence was detected by exposure to
Agfa X-ray ﬁlm.
Puriﬁcation of proteins and generation of SARS-CoV E protein
monoclonal antibody
Recombinant histidine-tagged SARS-CoV E and PRRSV Gp5 proteins
were expressed in the baculovirus/insect cell system. Recombinant
proteins were puriﬁed to near homogeneity by Ni2+-NTA afﬁnity
chromatography (J. L. Nieto-Torres, M. L. DeDiego, E. Alvarez, and L.
Enjuanes, CNB-CSIC, Madrid, Spain, unpublished results).
Puriﬁed E proteinwas the basis to generate the SARS-CoV E protein
monoclonal antibody by immunizing BALB/c mice. Positive hybrid-
oma cloneswere selected by ELISA, immunoﬂuorescence andWestern
blot (J. L. Nieto-Torres, M. L. DeDiego, E. Alvarez, and L. Enjuanes, CNB-
CSIC, Madrid, Spain, unpublished results).
Analysis of viral RNA synthesis
Viral RNA synthesis was quantiﬁed by Q-RT-PCR. cDNAs were
synthesized from 50 ng of total RNA extracted from SARS-CoV-wt,
SARS-CoV-ΔE or SARS-CoV-EtagCt infected cells using speciﬁc reverse
sense oligonucleotides to genomic or subgenomic messenger RNA
(sgmRNA) of genesM, 6 andN (DeDiego et al., 2007). The High Capacity
cDNA Transcription kit (Applied Biosystems) was used in reverse
transcription following themanufacturer's instructions. To analyze viral
RNA synthesis a SYBR green assay (Applied Biosystems)was used. PCRs
wereperformedusinga virus senseprimer complementary to the leader
sequence, and speciﬁc reverse oligonucleotides to genomic or sgmRNAs
(DeDiego et al., 2007). Data were acquired with an ABI PRISM 7000
sequence detection system(Applied Biosystems) and analyzedwithABI
PRISM 7000 SDS version 1.0 software. Levels of viral RNAs are
represented in comparison to reference levels from cells infected with
SARS-CoV-wt.
Cell extracts
Vero E6 were grown to 90% conﬂuence and infected at an moi of
0.1 with rSARS-CoV-wt or rSARS-Co-EtagCt. After an adsorption
period of 1 h the inocula medium was replaced with fresh DMEM
containing 10% FBS. At 40 h post-infection the cells were washed
twice with ice-cold phosphate-buffered saline (PBS), scrapped off the
plates and lysed in a buffer containing 10 mM Tris–HCl pH 8, 150 mMNaCl, 0.5 mM EDTA, 1% IGEPAL CA-630 (Octylphenyl-polyethylene
glycol, Sigma) and protease inhibitor cocktail (Roche) and incubated
at 4 °C for 20 min. The extracts were clariﬁed by centrifugation at
10,000×g for 15 min. The supernatant was collected and the total
protein concentration was determined with Coomassie Plus protein
Assay (Pierce) and cell extracts were aliquoted to avoid repeated
freeze/thaw cycles.
Tandem afﬁnity puriﬁcation
Cell extracts (4 ml) at a protein concentration of ∼5 mg/ml were
incubated with 30 µl of Red Anti-HA Afﬁnity Gel (Sigma) overnight at
4 °C in an orbital shaker. Agarose beads werewashed 10 timeswith 10
volumes of wash buffer containing 10 mM Tris–HCl pH 8, 150 mM
NaCl, 0.5 mM EDTA, and 0.1% IGEPAL CA-630 and then, protein
complexes were eluted from the matrix by incubation with 500 U of
AcTEV protease (Invitrogen) for 3 h at room temperature. Eluted
complexes were incubated with 30 µl anti-FLAG M2 Afﬁnity Gel
(Sigma) overnight at 4 °C and then beads were washed 10 times with
10 volumes of wash buffer. Protein complexes were eluted by
competition with FLAG peptide (Sigma) at a ﬁnal concentration of
1 mg/ml diluted in a buffer containing 10 mM Tris–HCl pH 8, 300 mM
NaCl, 0.5 mM EDTA, and 0.1% IGEPAL CA-630. Proteins were
precipitated by trichloroacetic acid at a ﬁnal concentration of 10 %
(v/v) and then were resuspended in 30 µl of NuPage Sample buffer
(Invitrogen) and incubated 10 min at 65 °C. Puriﬁed proteins were
loaded into 1.0 mm NuPAGE 4–12% Bis-Tris gels (Invitrogen) and
electrophoresis was performed at 100 V using the MES SDS running
buffer from the samemanufacturer. The gels werewashed three times
in deionized water, stained with Coomassie blue Simply Blue Safe
Stain (Invitrogen), and the protein bands were excised from the gels
for their identiﬁcation by mass spectrometry.
Identiﬁcation of proteins by mass spectrometry
Excised protein bands were in-gel digested with sequencing grade
modiﬁed porcine trypsin (Promega). Peptideswere extracted from gel
bands in 0.5% triﬂuoroacetic acid, dried by speed vacuum centrifuga-
tion and resuspended in 4 µl ofMALDI solution. A 0.8 µl aliquot of each
digestion was deposited and dried onto a 2386-well OptiTOF™ plate
(Applied Biosystems) and co-crystallized with 0.8 µl of matrix
solution (3 mg/ml CHCA in MALDI solution). Samples were analyzed
by matrix-assisted laser desorption/ionization time-of-ﬂight mass
spectrometry in an ABI 4800 MALDI TOF/TOF mass spectrometer
(Applied Biosystems) at the proteomic facility of the National Center
of Biotechnology (CNB-CSIC, Madrid, Spain). Data were analyzed
using the ABI 4000 series explorer Software v3.6 and searches were
performed with the MASCOT software v2.1 (Matrix Science) against
the MSDB from the non-redundant NCBI protein database with mass
tolerance of 100 ppm. No restrictions were imposed for protein
molecular weight, although in some cases taxonomy restrictions for
the viral, human or mammalian databases were included.
Plasmid construction and in vitro transcription/translation
The plasmids used to generate the SARS-CoV nsp3 protein
fragments were engineered by inserting the PCR products digested
with EcoRI/XhoI in the same sites of pcDNA3 (+) plasmid. The
corresponding nucleotides (nt) of each fragment in the SARS-CoV
genome are the following: i) fragment 1 (F1), nt 2719–4896; ii)
fragment 2 (F2), nt 3886–5829 ; iii) fragment 3 (F3), nt 4888–6672;
iv) fragment 4 (F4), nt 6397–8484; v) fragment UB1-AC, nt 2719–
3055; vi) fragment ADRP, nt 3269–3814 ; and vii) fragment SUD, nt
3815–4896. The in vitro transcription/translation reaction was
carried out with the TNT® coupled reticulocyte lysate system
(Promega) according to the manufacturer's instructions. Biotinylated
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detection of the expressed proteins with streptavidin conjugated to
peroxidase (dilution 1:5000).
The pcDNA-E plasmid used to express the SARS-CoV E protein was
engineered by inserting the PCR product digested with EcoRI/XhoI in
the same sites of pcDNA3.1 (+) plasmid.
The pcDNA-UB-OK plasmid that expresses a mutated ubiquitin
fused to His tag, which is unable to form poly-ubiquitin chains, was
kindly provided by Manuel S. Rodriguez (CIC-BIOGUNE, Spain).
The HA-PMLIV plasmid, expressing the PML protein fused to HA
epitope, and used as ubiquitination positive control in culture cells,
was kindly provided by Jin-Hyun Ahn (Sungkyunkwan University
School of Medicine, South Korea).
Immunoprecipitation
For immunoprecipitation assays Protein A/G Plate IP Kit (Pierce)
was used following the manufacturer's instructions. Brieﬂy, coated
plates were incubated with the appropriate antibodies (polyclonal
anti-nsp3 or monoclonal anti-E) diluted in the immunoprecipitation
buffer (PBS, 1% Surfactant-Amps X-100) for 2 h at room temperature.
Then, antigen samples were diluted with 1 volume of immunopre-
cipitation buffer and were incubated in the coated plates overnight at
4 °C. The wells were washed ﬁve times with 200 µl of immunopre-
cipitation buffer and then immune complexes were eluted with 50 µl
of elution buffer. Analysis of precipitate complexes was carried out by
SDS-PAGE and Western blotting.
Confocal microscopy
For confocal microscopy, Vero E6 cells grown on glass coverslips
were infected with rSARS-CoV, rSARS-CoV-ΔE and rSARS-CoV-EtagCt
at an moi of 0.5. At 15 h post-infection the growth medium was
removed and cells were washed twice with PBS and ﬁxed with 8%
paraformaldehyde for 30 min at room temperature. Then, cells were
washed twice in PBS, and permeabilized for 10 min with 0.2% Triton
X-100 in PBS. All antibody incubations were carried out for 1 h in PBS
containing 10% FBS. The immunoﬂuorescence was done with
monoclonal antibodies speciﬁc for HA tag (dilution 1:1000; Sigma),
or polyclonal antibodies against E (dilution 1:2000; kindly provided
by Shen Shuo, Institute of Molecular and Cellular Biology, Singapore)
and nsp3 (dilution 1:500; Rockland, Gilbertsville, PA). Coverslips were
washed three times with PBS between primary and secondary
antibody incubations. Alexa 488- or Alexa 594-conjugated antibodies
against the different species (dilution 1:500; Molecular Probes) were
used as secondary antibodies. Coverslips were mounted in ProLong
Gold anti-fade reagent (Invitrogen) and examined on a Leica SP5
confocal microscope (Leica Microsystems).
In vitro ubiquitination assay
For a standard reaction, 1 mg of the baculovirus produced SARS-
CoV E protein was incubated in a 10 μl reaction including an ATP
regenerating system (50 mMTris–HCl pH 7.6, 5 mMMgCl2, 2 mMATP,
10 mM creatine phosphate, 3.5 U/ml of creatine kinase and 0.6 U/ml
of inorganic pyrophosphatase), 10 ng ubiquitin, 50 ng human E1 and
500 ng human E2 (Ubch5). Reactions were incubated at 37 °C for 2 h.
After terminating the reactions with SDS sample buffer containing
mercaptoethanol, reaction products were fractionated by SDS-PAGE.
Detection of ubiquitinated and non-ubiquitinated E protein was done
by Western blot using an antibody speciﬁc for E protein.
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